Topic resource collection
Approved comparison material connected to this topic.
6 resourcesRead both sides
GLP-1 receptor agonists (semaglutide, liraglutide) bind selectively to GLP-1 receptors expressed in pancreatic beta cells, hypothalamic satiety centers, and gastrointestinal smooth muscle. The mechanism produces three primary eff…
The SURMOUNT clinical program (tirzepatide) and STEP program (semaglutide) used near-identical Phase 3 trial designs. Randomized, double-blind, placebo-controlled studies in adults with obesity or overweight plus weight-related c…
Tirzepatide Dual GIP/GLP-1 agonist ~5 days Adipocyte lipolysis regulation + insulin secretion + gastric emptying delay 20.9% mean weight reduction (SURMOUNT-1, 72 weeks) Best choice when hepatic steatosis, lipid panel improvement…
Research design for metabolic syndrome requires matching peptide mechanism to the specific pathway under investigation. The table below compares primary mechanisms, relevant endpoints, and protocol considerations for the major pe…
GLP-1 Agonists (Semaglutide) GLP-1 receptor activation → delayed gastric emptying, reduced appetite Fasting glucose, triglycerides, waist circumference 0.25–2.4mg weekly SC Subcutaneous injection Gold standard for multi-component…
The following table compares the primary peptides studied for metabolic syndrome intervention based on mechanism, clinical evidence, and metabolic targets. This comparison is drawn from peer-reviewed trials and preclinical studie…